Literature DB >> 25759370

Periostin Enhances Migration, Invasion, and Adhesion of Human Endometrial Stromal Cells Through Integrin-Linked Kinase 1/Akt Signaling Pathway.

Xiaoxuan Xu1, Qiaomei Zheng1, Zongzheng Zhang2, Xiaolei Zhang1, Ruihan Liu1, Peishu Liu3.   

Abstract

Although our previous study confirmed that periostin (PN) was overexpressed in the eutopic and ectopic endometrial stroma of women with endometriosis by immunohistochemitry, the role of PN in the pathophysiology of endometriosis remains unknown. Thus, we aimed to investigate the effects of PN on endometrial stromal cells (ESCs) migration, invasion, adhesion, and proliferation and to further study the mechanism under this process. Eutopic (EuSCs), ectopic (EcSCs), and normal ESCs (NSCs) were isolated and cultured. We evaluated the above-mentioned biology behaviors and the expression of PN, integrin-linked kinase 1 (ILK1), and phospho-Akt (p-Akt) in NSCs, EuSCs as well as EcSCs before and after receiving PN small-interfering RNA (siRNA). The protein and messenger RNA (mRNA) levels of PN were upregulated in EuSCs (P < .05; P = .2261 in proliferative phase and P = .3385 in secretory phase) and EcSCs (P < .001; P < .001 in proliferative phase and P < .05 in secretory phase) compared with NSCs, although there was no significant difference in PN mRNA between EuSCs and NSCs. In EcSCs, abilities of migration, invasion, and adhesion and the expressions of ILK1 and p-Akt were enhanced; and all of those were downregulated after PN siRNA interference. Thus, PN enhanced ESCs migration, invasion, and adhesion due to the ILK1/Akt signal pathway. As an agonist in the development and progression of endometriosis, PN may be a new clinical treatment target of endometriosis.
© The Author(s) 2015.

Entities:  

Keywords:  ESCs; ILK1/Akt; adhesion; invasion; migration; periostin

Mesh:

Substances:

Year:  2015        PMID: 25759370     DOI: 10.1177/1933719115572481

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  7 in total

1.  Controlling Semi-Invasive Activity of Human Endometrial Stromal Cells by Inhibiting NF-kB Signaling Pathway Using Aloe-emodin and Aspirin.

Authors:  Nahid Nasiri; Sara Babaei; Ashraf Moini; Poopak Eftekhari-Yazdi
Journal:  J Reprod Infertil       Date:  2021 Oct-Dec

2.  Periostin silencing suppresses the aggressive phenotype of thyroid carcinoma cells by suppressing the Akt/thyroid stimulating hormone receptor axis.

Authors:  Min Wang; Chunyi Gui; Shenglong Qiu; Jingdong Tang; Zhihai Peng
Journal:  Cytotechnology       Date:  2017-09-30       Impact factor: 2.058

3.  Concurrent nicotine exposure to prenatal alcohol consumption alters the hippocampal and cortical neurotoxicity.

Authors:  Dwipayan Bhattacharya; Ayaka Fujihashi; Mohammed Majrashi; Jenna Bloemer; Subhrajit Bhattacharya; Manal Buabeid; Martha Escobar; Timothy Moore; Vishnu Suppiramaniam; Muralikrishnan Dhanasekaran
Journal:  Heliyon       Date:  2020-01-08

4.  Impaired ILK Function Is Associated with Deficits in Hippocampal Based Memory and Synaptic Plasticity in a FASD Rat Model.

Authors:  D Bhattacharya; E P Dunaway; S Bhattacharya; J Bloemer; M Buabeid; M Escobar; V Suppiramaniam; M Dhanasekaran
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

5.  Periostin Facilitates the Epithelial-Mesenchymal Transition of Endometrial Epithelial Cells through ILK-Akt Signaling Pathway.

Authors:  Qiao-Mei Zheng; Jing-Jing Lu; Jing Zhao; Xuan Wei; Lu Wang; Pei-Shu Liu
Journal:  Biomed Res Int       Date:  2016-03-13       Impact factor: 3.411

6.  Identification of Circular RNAs as a Novel Biomarker for Ovarian Endometriosis.

Authors:  Xiao-Xuan Xu; Shuang-Zheng Jia; Yi Dai; Jun-Ji Zhang; Xiao-Yan Li; Jing-Hua Shi; Jin-Hua Leng; Jing-He Lang
Journal:  Chin Med J (Engl)       Date:  2018-03-05       Impact factor: 2.628

7.  Emodin Reverses the Epithelial-Mesenchymal Transition of Human Endometrial Stromal Cells by Inhibiting ILK/GSK-3β Pathway.

Authors:  Qiaomei Zheng; Jinhua Wang; Wenwen Li; Xiaoyun Chen; Shaozhan Chen; Lihong Chen
Journal:  Drug Des Devel Ther       Date:  2020-09-10       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.